AUTHOR=Edinoff Amber N. , Doppalapudi Prithvi K. , Orellana Claudia , Ochoa Caroline , Patti Shelby , Ghaffar Yahya , Cornett Elyse M. , Kaye Aaron J. , Viswanath Omar , Urits Ivan , Kaye Adam M. , Kaye Alan D. TITLE=Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review JOURNAL=Frontiers in Psychiatry VOLUME=12 YEAR=2021 URL=https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.699748 DOI=10.3389/fpsyt.2021.699748 ISSN=1664-0640 ABSTRACT=
Given the typical age onset of schizophrenia, there are tremendous economic and social impacts that extend beyond the person and their families. One critical determinant of the diseases' impact is the patient's adherence to antipsychotic drug treatment. Approved in 2015 for the treatment of schizophrenia, paliperidone palmitate (Invega Trinza, a 3-month injection, noted as PP3M) is a second-generation long-acting injectable antipsychotic medication. Among the different formulations offered for palmitate paliperidone, including the 1 and 3-month formulations, the longer duration 3-month formulation was better at preventing relapse in schizophrenic patients. To date, different formulations of palmitate paliperidone that have been studied on relapse episodes of schizophrenia include once-daily extended-release oral paliperidone (ORAL paliperidone), once-monthly paliperidone palmitate (PP1M), and once-every-3-months paliperidone palmitate (PP3M).